Abstract
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Tibaldi J. Importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes. South Med J 2009;102:60–66.TibaldiJImportance of postprandial glucose levels as a target for glycemic control in type 2 diabetes.South Med J200910260-662. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005;21:2029–2035.WeissmanP]]GoldsteinBJ]]RosenstockJ&etal;Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.Curr Med Res Opin2005212029-20353. Al Majali K, Cooper MB, Staels B, et al. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 2006;49:527–537.Al MajaliK]]CooperMB]]StaelsB&etal;The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.Diabetologia200649527-5374. Mori Y, Itoh Y, Obata T, et al. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine 2006;29:143–148.MoriY]]ItohY]]ObataT&etal;Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.Endocrine200629143-1485. Bell DS, O’Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 2008;14:112–124.BellDS]]O’KeefeJH]]JellingerPPostprandial dysmetabolism: the missing link between diabetes and cardiovascular events?Endocr Pract200814112-1246. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004;27:2585–2589.OvalleF]]BellDSEffect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes.Diabetes Care2004272585-2589
